UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported):
___________________________
(Exact name of registrant as specified in its charter)
___________________________
(State or other jurisdiction of incorporation or organization) |
(Commission File Number) | (I.R.S. Employer Identification No.) |
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including
area code:
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
___________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by
check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbols(s) | Name of each exchange on which registered |
The |
Item 8.01 Other Events.
As previously reported, on February 27, 2024, CNS Pharmaceuticals, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the last 30 consecutive business days the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”).
On July 5, 2024, the Company received a letter from Nasdaq notifying the Company that it had regained compliance with Bid Price Rule as a result of the closing bid price of the Company’s common stock being at $1.00 per share or greater for the 20 consecutive business days from June 5, 2024, through July 3, 2024.
Accordingly, the Company is in compliance with the Bid Price Rule and Nasdaq considers the matter closed.
2 |
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CNS Pharmaceuticals, Inc. |
|||
By: | /s/ Chris Downs | ||
Chris Downs | |||
Chief Financial Officer | |||
Dated: July 9, 2024 |
3 |
Cover |
Jul. 05, 2024 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Jul. 05, 2024 |
Entity File Number | 001-39126 |
Entity Registrant Name | CNS Pharmaceuticals, Inc. |
Entity Central Index Key | 0001729427 |
Entity Tax Identification Number | 82-2318545 |
Entity Incorporation, State or Country Code | NV |
Entity Address, Address Line One | 2100 West Loop South |
Entity Address, Address Line Two | Suite 900 |
Entity Address, City or Town | Houston |
Entity Address, State or Province | TX |
Entity Address, Postal Zip Code | 77027 |
City Area Code | (800) |
Local Phone Number | 946-9185 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common stock, par value $0.001 per share |
Trading Symbol | CNSP |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | true |
Elected Not To Use the Extended Transition Period | false |
B3,3QJ-PM9J7D+B^"JP4(Q M&"P$:<;+/-P/!P<'*>2VO&8!Q2=R?W^9@XVUZZTN:=>78R'^"1U-U-]2*ML.3 M7?6R.?C6_25",/^:J-W->!S&Y9%=D@"]"K!#B8['P"[3PH::24<9:HB[>/G4 M4<8DOT.0R&9,]W-Z<6&=U.9ID+OS:K.!;&%^R\9-;[0"_;CZ7L^KCQ=UUEO9 MD6 -@]OC9H)+D?WXUV4=9LH<(FOYKG_1T$X+\ MA*@K"C4L!B/V?N/;IP/;]/$_,)/KB"\96S>\'=:!+?E 'NIL#C C0PE+?F(N M5W,,AEM+8 B!'I'F5 F9$VBK;H+SYHGBC@U>K^HF2*NZ-,>Z:L+UI7P[[BA7 MXJNL*^"=,8>-6W2;&:;^@*HZXYZ%6?-;R&N\W&(/5*(+3<_[U9;FREUX-[EG M0W(_DA4&+/:8&2WDW5/%."^>G=;DP>HN+#LKPV>ZF)?))++%C+#[1IF]GZ[F M0S+KTE'#2QR)7 <6"?#$%GY)H\O"V8BM+L"(S-\<)B"Z%Q)"-K.7S^67%"=\ M,U_C(KQ?WNHFYZP:W)XP@-8A<#;)+PAH+4EV(VN]S_WI.Y*7@Z;-N3 '5).? M^&>^.$5JX!JT;JNJJZILX9$I0>,@[GQN+U+\=9!M)-O)3I+454/1QR#PL%*1 MEI[ 1G'4<$ _&R #$$^8$;J::N&Z2C._9PCOO8F=E:[;TP0"%Z@-^[0NU! MK8ZZUX75![B[S "%>+GCR.!68#(^,B1^<67Q>*["K^=F5W_4HB57%9L_K\:C M9J[U!M4HS)7<,_EX^41W+%O7YNE";'%4YR'D/OW Z>9 MQNGE.T9S>W,'/<5CO-QE(VK-&?>,"=2CAGVA S/*K6S,CV&O^GM[NB+>" ]O ML('BW$&%.(B7"X7T[+G@1O>$'E^X(31,D+-L4(6P$1-AV_J ^T18>)BU'=L" MG@DRO 1\_T0>O[I,ISTU*L@ZZ6-"G$'6YF]Y^2_WG/ M!NS%.:O*@I]NVKGK/@H1_P>(M]\?>0UG#V![ DD(>O6%UR,3?>#Y!J $K M)CAD6 )C/7U$>DS1'W&BL!'G#TO$2%]6P%<1V0+'93- )N&QAR6KCF)3C4&D MH(R)!?L&JS_F/;T.>@^X\794+LI ,M !/":AVMAOZ^L*$$>GB*NXC!LBBVP= MR&6+,3S.+A\SC9FP;#0T0.&X.\-*4DBZ7&^7WFT:/6F^^S*R>-9F]W-]JLK* MN/12:=2TA][U//0/4[9A.G'_Z6C>OL^*=M.=DT;VIG_;;=:$58.T4D_7%48U M7APUYX%FO#/T,5_9QD1X>%"F2L#<[ %8$_4J+U ML'Y[G>D]-9OJ_? ]]#"4KYSE:2U*^(PVIGIX9S4PDZ.)C!!0PM"Q[D0% AA1MUJ*5@#XA!O"_Z",S.2DA;/6VE]-1%_9+2]^BI4*TEC8LRV'FB[HZN+D\&]/J MK]/CUYWG+*FK^06Z.L/A!VELEB5R6^)R&NO!OE\68KWY\Y6P1>KP$EN->+FA M22AG1GIC(O+-!$#])H]#QL]NIB)]V#> (L,D(:(!&9CZHSW$Z3(P^J<6D5A? MUMR2 #?^2N?]3<%4\.46-&7)%HJRL,]C,!\8R,!L&EA,@+M/=\Z%7D*(P.5/ M?"Q0)35!BO/_W"^ -OF9 ^V-?FEL*)7Y_<,:=6=8E%>Z3> MGOKPLV@]/1G*6ST2; >G'5+$^4 D;YXOVGW!%_U1,_\&P^U'F**O$YB7G-AU M+\LSF?0A6RQ0FVF"UFLY]K&,Q#@6\>2D"? =0YKMT]PT&G#E.2QDC\4<9 M2*,J:C!.:#$9;/JA'_@"JHD8%E.1ORR'H3*^@"E14P*_CLD!Q&]$EF!N4;_X M,N3=DR2X=JQ/^X_"VC_J3@;M5O)%J[Y^ W/CL9%#+B)EL;@JHHOOPKKUQ2+X185:UJ(Z#&^< M7#5FN/,:^3H\O]G7HIEV;R3"JB,Q* L+6MA0 #K'X 4-DW)8=6A>NVN/LZTKC#XZ>6FYN?+7' /[%8[N1*>H.L0P?Z(:*\UOOB M4PBQ"^O:O$-A7W_\T&Q^"7WA.J]WCH]_"O?2F\I"T&-$581DTU%Z'>0+7$^E M4ZM ! T-'Y7LY[S7QFLDU& M?R=Z#%PS<&EP!5EN@B<*&E"[H!T&"0;'AI+@>K=&'7\+HC7[#EBVP5X&INYH M$BJT#ILCB(;QA<KEA,Y7L)=,9+/I9G$,'Z'/,V,;J^!:EE5QCF= "'C Y#=LAC_S=2=&-;WLY[I4'-,A(+[3N<.F7\YTQ8F"+"( M4$CO>\E*_BFSOPU8128_,(E0GCP79;#D,7@?&UP&Z9NZRK,+3=@9X1[PT@'F M_&82HM&Q:;\_H0 [+@SD6M22Z/U,K(.Y ?(/'RI8])5-QR"(L_SRSYYCR1J6ATIT;'&HGBQAH:C()OT"(N!5 ME6)@XT&&5(+=NH[I0[>$"7NHLB:KCDK^G8&MR/-.!(1W[\BF>VCDIB0QQ^CP M PA1$ M4+[,UG6H\%HU7;,5+G,@FL> Y$\SUW.-!-^RWD'5B?F:&["SH'%YD[Y VV6; MZZ3)!I0?;?&TMXR7"+IY[[ NX"$8!6#+46P_-8CJC)GO9TOP&A8:0H\A.\# MM-*#G@]@'>9#\"Q*2)/Y1LC'>>IH;"*8F#T$^0V&KKBR[M,O[?W@Q484(:Z% M.5?&.T'MB/%BS1FU0XAIU=,D7Y]1&V0(DET7#-MHU!;7K7[Z>?Y"]87J"]47 MJB]4_T14+^>AA*\\U&;S4"AOX2OC]&%&L710NZ8,UWK*F5QM6[+H8O):M4>2 M(Y*8Z%WC4'(K/?%2\GBY ^BI[>!!Y!K>^EN9Y8V?7DS,]Z-?/A,*.'[_WKR8 MK7LU99- (UFV[>#3,T/48LX L:='[E%#P8 M4J6/-6Z(B.N(!S!D)G,TZ,/14<<>ZB9XX+7M?MZI\'/-%[*^ W^?$.7GJ9,* MKHZ3XW_ A'[N,"X$5[65#T$6W#0W=37.S%J]^B5D^4PX6IEW_]-R4/FEP#)3 M- -#F.D2.98%)%X+SW,@"50_AE?9/YH4PKQI)*X;?A/=5U\$%4'KA:*0;^,2 M67B5U^Q0ERO666+I3UDI4AV:LL6)UO1'S5I\++;Y[PL*>=8^4:^?/"X\5W!_ M+( .G_/[1,P/X_:%9Z^FB[?!PC:#9]Z+_G6PZV+BS[W1ZV-JF_ZH M 4Q6X+7&.U_HOM!]H?M"]UG0+4CL9@,%;_Q"H:\\[[OG>:^QQ)^+?CKCF]UD MQO=/+OE[%T2QY?[RVMZW._X6IGN%TN0/MK'3T=&OJ_3WQU^5R^%5ZO+\<70K MY[+MGGF?OF\,KXUO[='Q?T=7 U50N^?-_N_>6*$W5JY6>:JQ8K%P^?NI/K2I M>GG3>[(L>3AJWIIV7=2M^NTQVSL9C)NT<'36L/>.[\5;(5O ;5[DFG_8H/>Y?6) MH>=:S,H^G-&3JV:A>?6@L_MZH?%T>W1^TV57>C]=.U5O&K6+?J?[W_.;P=/3 M6;M[0T]'C9Z1'?S\N>O\;!?ECG6LCFI:^\%(I6_[E?MOWX>#PT-7(BG\.W/\ M#QC:JE+^?U!+ P04 " F6^E8C76,?RH# #F"P $0 &-N '-DM5;; @D<8H0;X@@AB4%!V"5YA MF"@+O<,A8J!-HSA$ DE''JD!ZI9;@\ T]]!]1<2G[*77F>N.A8AYP[:GTZE% MZ 1.*7OCED>C_03[ HJ$S]6J:;7X[4=_P-R;DROW-*9G:0\/1HB<)Y^'@_CA M"59N*O!9S.IUM_+C+9U$/3?PW^X'LW.>_GHZ_8J]BG/KN]^\DTX>LLF],8H@ MD(=!>,M0]17E36L692/;K58=>_#0[6 !],2 L@4\QBQ#="<]<*H?W8?YYC M/<+C,6015$V9P:IGU;H >TVE1># M ;#?,O+EDIK6\U& " 2:5T1T@1&B,FL&SII8L@ M3QT+17]>"@-4'&X ^Q]6'L+AH95+"@K_8\E=I5^NM6FOCI;\7A^_IBR7,@%( M:9!W7:3Y$]"E7B:U@Z*^3,TSE DL1B!PY+0O..2&++=;XI M/M\&5XNLA?8-NN59V!ET(\=&H>#: 7@ MFUJ@:>=J &ULS9U=;^.X%8;O"_0_L.Y-"XSCB;,MD.QD%QE/LC V MFZ2Q9[;MHEC0$N,(H 41%FB>"0E14G.Q8Q'? _U4GQ,4E_'GW[< M;2AZ(2)-.#L?'1]]'"'"(AXG;'T^^KH87RQF\_D(I1EF,:: $"]WPB+N?AZ/Z_J? O)$1?KR?3CQ^/)/W^Y7D2/9(/'"5/'+2(C':5JL<4=GYZ>3O)2+6TI=RM! M]3Y.)MI.5;,L33KT-2=I3//LOVS1"E-% FC T=$PN-+]C[79K0G^_*[([+_ MH0'U>.=-6/(,TW>9KT RT\-BV27R0F,Q-JDJJ)C!,[WD$\,9=U5[3QJU$O5:,Y%N^UJ9LSK3$ET MM.8ODY@DLN[I=^K#6'W(FRW_\_N,RY7 Q2K-!(XR75/>C/.1I7QB6E+*"Z%] M81'U-*Y43"(NIZ;G;$R+PUB$/PB^L>ZV;#6W%/Y.5U5\<5CD+@"C#9D@*=^* MB+RI5^INH:-4.MI0J5!+*L+&7Q>C'W(-^DVK_O-I KF+R2-1/*LEO-=[6C(G'>ZQ62K[VN:L!!H&X-)J&D] M#>SW9)VHJ4594.>W1&WL&,8 O>NAO].V.1=8Q4% ,\0A.%O4@U 5Y8FC"\:V MF-Z39RZZ\&G*7%-C,VG"4M<$Q8C%&(A&H46%V!,1_]C*,W8BZ+X7BI;2-1> M51,-0Q84'79O(""5W"\C2X%9FJ@!K!>2MM3YZ09@MG7J8>B"X@0P!Y^25'J_ MI"P>":7J?@!F_0.*3>R:%MBPR4M;&10QH#V0F3P"E2'A8'/YHE;G KN2VM*-Y%JUK M0$"[)B0M85"@0.Y 6(H S4P>XA68?Q$LAN%24_J!I675CDHE"Q 4TUL?)DKO M!9+95HB&:WC&@:7.;LKVF*WNSP*Z($#I,=>Z:UO(&Z!XFH$N699D>_4\W ! N *9.!0H:4#A5"+SVO[Q*P3#W$"#;'E+DEP&ZR M24%3$Q )5F, #0=M_DRI%R)F 2 M)=[-8PEJ\I 4SX/W4 +JW<+28[O)#" .")UNAP!!,@@UHWR"-&<1%\^\]KC# MC&_E +B?\1A>H?1$N85J4!.::'6&! 38$)\ 9HW0#\4S*8BK]WCR"I"JP0MQ M%W$L#U1:_G.=,'(,MM^J=4M7A]TF4Q9A0"3![@!^2N4'_0&I&'3+0H%F^H:F M3OU#,QT*S31H:*;O@6;YR@.!YN0-33WQ#\W)4&A.@H;FY%W0R([W.M;,Y,=; ML>2OMH>S0:479-I6K< <9.'ATO+6!XL*4.L9%>(3DWQA=2ON!'])6 0OF2&Y M%V TU9J#&UXZ-@-]O%3+8AUG->QIEB4]WY)M,S/*-,T:1]B"DUXD#2-]0XN MA=HG$G<\S3#]=_+<>2)N%WO!PVK8"DE#&1XJ-GM]P!0Q2 ;Y.+$N<54W-*RO MDAGE[EX!MM@ZO )<*PP" INC]BO Q=630N2ZFQ6C@F!@1&@6.^MDBZFJCVME M871QVU"KA_/OM=3X^"*K["[T[I$S^ &!ML153T/F=&^;Y4'T.*[/5 M=TTYJF=;GCWOQ5))G<\XQO-EM6WN6Q M/3<(Z%SU -641"]W^7,)*'4HJ;8,18+3I,HR1*V_D6>?(H$VUIE$[D" M C:H:6@K@D !M&5R"'A,&6M^QXDREYQ>; M?/]7\H.EE8#.64[++IM54DN;* A&NIRUTEH62>=J8J34KKG8QDE&XL+,5<(P MBQ),J_2(MBOB_2'.:!EHO@*G1Q\&0\-,MG JPG0NPRKPD.K2]:7TX@&,7PFE M/S/^RA8$IYR1N+B68KM3U*UW^\1,C^WF0S. . B ,G%85T6'DE MS M)WSC=L@R+_%UR81N9 )U;<@";36(,44"DV)T!A%1B5*C]O*!=9(^H%EG% M[PZ!#83DCE_7[C1MO+5MU0;$3*=!Z!WN,N?'86U<1'EZQ3(CZO X M] :V%Y*[?JFRR[3Y-J5-&Q!"G0;!]R>K&)4J!FNFO*6,$3.YU%KSCJ?$#97[ MQ#$MB^W<,94D(#QLOCHRR BDM5Y86&PPI9^W:<)("D]$ALHM"U:+318:DH!8 ML/D"6,BE2&N]L'"Y(6(MI[>?!'_-'LO\K +5;-CHM-QFQ2@-BI LL-S]"2HZ\I M0=DC09?ES]#5,\$7]?CZI9$H4B]$%*MR%F-A0ZA+[/Q71T##K=\>:2F# *G7 M'OP[)%4$TB&.J;F5#(OZ>5QN8IZ1#?BV0W^(*X*&FM<<]>F#H&F@29.I/*QY M 4 M8_@J2T/C.&->VYZ1+.\@"(B MBLH15XN1+G22_]_QNQ);)^S:'\G>$2(>LHJ MK4:KONMO Z/=,O.F)C5I&A0:$&=O\0L0>*@"U>KX4)NQ?%[,4P^-JVQN/'I: M/&)Y &^W6:IF4&D,O@K>&>3X]L* !A@W&3HB D)O@$WHAD,>B?+0#Z@(1K5H M3^=GZ2$+((D_[^_) Q'JO8,EV66?Y8Z>.LXP!L2Z/GL;W!SS9*XW, @(W^H6 M.M5+4;T"M%+/B)55H-]4)2BOQ?;[Y?5-U_*3W*PWR;]6."5RRW\!4$L#!!0 M ( "9;Z5CO[W &UL MS9Q=4]LX%(;O=V;_@S=['4)"NUTH; =2TLF4 DMHN[LW'<56$@VRE)%DDOS[ ME>PXS8 M[M%Q*Z(BE@D3TXO6 MUU'[ LOD?TY_ZW=C@:,\N0L^BCC]E!,Y/OH MEJ3T+/I$!57$2/4^^D9XYK;( >-417V9SCDUU'Y1-'P6O3WJG9"HW0;4^XV* M1*JO#\--O3-CYOJLTUDL%D="/I.%5$_Z*)8IK,*1(2;3F]J.E\?KGZ+X.6?B MZ E]$"Y'"M>MG'2*;NSJ=E^RP+ZK9YH=J;S[MW(F)@\[+7- M1%Z%^Z]=RMIN4[O;:Y]TCY8Z:97PCXC*B4N8AWW M;: F,W[!2A2V/W)YJ4%;GVP5TSS#CU>G?I1FVW;V6I; M:9Z[&,@]K^7^G)/6-#Z:RN=.0EG'^75Y M_3^L9D_2::!7)8E'6V-UIW85^WW:CMJEBB.I$JHLZ[(NHN*=6!WNFFM%9TZ4 MK:@=SQC?A'FB9.JCLR8A/1W=!F6;:(;FI6T_<7T8<#*MQKDG ?+L8@"M=(-% M]"/5L6)SQZ4&[(X2R+>'RK?"6\.8RV/G@4Z9ZZ_KBCOA4KC(D(SQP<"_% -)/X'ZH6'QR,2\M&,WF5'HC]'29VO\]7 /[Z MV9W?[:D%SGZK"!#_GZ\%_X%;I C<4\5D8D_I"L#^0 RD?HI)W>,0E?>U2*"T M-U)P_H,/>\\>$NH!TS'A18\&=IL.XZZ00Y&CY)RU-E&Q_TN) D/?$D.1HZ2A M-18;!M[/E-KI3'!4\:NAR%$2T#J3#3._%H:9E;OK?YNEXY\W3G=9'ZJ@C%&2 M3I\I%+;EG09AW,.,$-]])90Q2JX9,H?"N6_]*,*'(J'+SW05 GT@A9)&R3 M]E!0WRN6$K4:L;A^T#C40F&C9)9A@RBT'\ERF%A7;,**QX'UT+U%H.Q1TDJ0 M7900#$4LU5QNW2[NR\P>CZN^3()#>DU!:#A0\LT76$<)RF626%QZ_>>&"=H- MA:)2#GY&A!> @,U7@KWW,NP].':4/+36YBO!?O(R["=P["BY:*U-3.Q]^_%. M/ [4O9+/K)@554?]H 04/6**&C:+NL,7)WG( MWEXJH;P1T]5J K-XI+?JAU1M5+^5>4@D8!)>V#FFYZG*%Q9H>]5; 3^Y2&50BAAE 0O8*UAR#O]J,:[)X&" M1 68IJ7PBJ/(< QXI%#GBLT.//9RYE\6D MYLVYIWAA1XBXKP04/.)#Q+!9I/EIAKH^LV?ZD1BR[F&(OZ\$E#_B \6P6;3Y M\ZIO3SQ3&7YFOB>$TD:<"EMI#07R*"6<7V6:":J#8\N>$ H9< E#HB#-;@U9QX"]_KB,OUK\%R5>HP6\G0,3N-8GU MVHTX=A,IBC.Y2(CR4 _IH=Q1%U;ZC39,_L[,J-J^?LH[,[1Y6VC20WTI:!10 MTE6H:9QSZ]9*_N"I=4<'Y8V8F%89PUDSE8TYBP= F?"[UH -W>#>4%M\XWZYM[#:+?\#4$L! A0#% @ M)EOI6&CF(DVN$@ NW0 H ( ! &-N&UL4$L! A0# M% @ )EOI6._O=SI6!P UU< !4 ( !8"$ &-N